| 28.53 3.68 (14.81%) | 05-29 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 34.84 | 1-year : | 40.69 |
| Resists | First : | 29.82 | Second : | 34.84 |
| Pivot price | 26.34 |
|||
| Supports | First : | 21.65 | Second : | 16.6 |
| MAs | MA(5) : | 25.57 |
MA(20) : | 25.15 |
| MA(100) : | 20.56 |
MA(250) : | 24.14 |
|
| MACD | MACD : | 1.6 |
Signal : | 1.8  |
| %K %D | K(14,3) : | 53.5 |
D(3) : | 49.4 |
| RSI | RSI(14): 68.5 |
|||
| 52-week | High : | 71.5 | Low : | 8.72 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ QURE ] has closed below upper band by 18.9%. Bollinger Bands are 15.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 29.5 - 29.64 | 29.64 - 29.77 |
| Low: | 27.25 - 27.4 | 27.4 - 27.55 |
| Close: | 28.27 - 28.52 | 28.52 - 28.75 |
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Sat, 30 May 2026
Mizuho downgrades UniQure NV (QURE) - MSN
Sat, 30 May 2026
What Just Happened with uniQure's Earnings and FDA Update - Kavout
Fri, 29 May 2026
What Caused uniQure's Dramatic Stock Plunge - Kavout
Fri, 29 May 2026
uniQure stock surges 20% on Replimune FDA BLA news - Investing.com
Thu, 28 May 2026
QURE Technical Analysis | Trend, Signals & Chart Patterns | UNIQURE NV (NASDAQ:QURE) - ChartMill
Wed, 20 May 2026
Considering Uniqure NV (QURE) Stock? Read the AMT-130 Message - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 63 (M) |
| Held by Insiders | 4.981e+007 (%) |
| Held by Institutions | 5.5 (%) |
| Shares Short | 10,980 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.7486e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 321.1 % |
| Return on Equity (ttm) | -17 % |
| Qtrly Rev. Growth | 1.809e+007 % |
| Gross Profit (p.s.) | 146.32 |
| Sales Per Share | -262.35 |
| EBITDA (p.s.) | -1.30609e+008 |
| Qtrly Earnings Growth | -3.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -172 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.11 |
| Price to Cash Flow | 7.78 |
| Dividend | 0 |
| Forward Dividend | 1.078e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|